Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

ChatGPT doesn't know much about drugs, Hims & Hers enters weight-loss market

Dec 05, 2023 - statnews.com
The article discusses various issues related to health technology. It highlights a research letter in JAMA Internal Medicine that reveals a troubling pattern in hospital record-keeping, where electronic health records do not always reflect patients' death. It also discusses a study that found OpenAI’s generative AI tool ChatGPT to be ineffective at tackling drug-related questions. The article also mentions the tension between enthusiasm for artificial intelligence and skepticism in the healthcare industry. Furthermore, it discusses the unveiling of a new business line focused on weight-loss by San Francisco-based direct-to-consumer telehealth startup Hims & Hers Health.

The article also touches on the issue of immediate access to imaging results by patients versus the need for doctors to have more time to interpret the results. It mentions the debate on this issue at the Radiological Society of North America meeting. Lastly, it discusses the FDA's controversial plan to regulate tests developed by labs in academic medical centers and hospitals, which has received over 19,000 comments from the public. The article concludes by noting that the volume of comments shows the level of concern this rule is causing in the diagnostics world.

Key takeaways:

  • A research letter in JAMA Internal Medicine found that electronic health records often do not reflect patients' deaths, with about 19% of deceased patients in a study being listed as alive in their records.
  • OpenAI's generative AI tool ChatGPT struggles with drug-related questions, according to a study presented at the American Society of Health-System Pharmacists midyear meeting.
  • Direct-to-consumer telehealth startup Hims & Hers Health has launched a new business line focused on weight loss, potentially positioning itself as a competitor to companies like Ro.
  • The FDA's controversial plan to regulate tests developed by labs in academic medical centers and hospitals has received over 19,000 comments from the public, indicating significant concern within the diagnostics industry.
View Full Article

Comments (0)

Be the first to comment!